Schwarz ES, Buchanan J, Aldy J, Shulman J, Krotulski AJ, Walton SE, Logan BK, Wax P, Campleman S, Brent J, Culbreth R, Manini AF, Toxicology Investigators Consortium Fentalog Study Group
Morbidity and Mortality Weekly Report (MMWR)Summary
What is already known about this topic?
Medetomidine, a veterinary anesthetic drug, is an emerging adulterant detected in illicit drugs, drug paraphernalia, and overdoses.
What is added by this report?
During August 2022–July 2023, medetomidine was detected among five patients along with xylazine, fentanyl, and illicit opioids. No permanent sequelae were reported. All patients received naloxone; however, only two received naloxone kits at discharge, and only one was referred for addiction treatment.
What are the implications for public health practice?
Medetomidine is an emerging adulterant detected in illicit drugs; further investigation is important to better understand the clinical effects of medetomidine and other novel adulterants. Programs to improve addiction treatment and naloxone distribution are needed.
FULL ARTICLE
This email address is being protected from spambots. You need JavaScript enabled to view it.
